[Sentinel lymph node in nonmelanoma skin cancer]

Area of Science:

• Oncology
• Dermatology
• Surgical Pathology

Background:

• Sentinel lymph node biopsy (SLNB) is standard in melanoma due to its strong prognostic value.
• The application of SLNB is expanding to other skin tumors beyond melanoma.
• Limited data exists on the prognostic significance of SLNB in nonmelanoma skin cancers.

Purpose of the Study:

• To critically review the literature on sentinel lymph node biopsy in various skin tumors.
• To assess the current usefulness and prognostic value of SLNB in nonmelanoma skin cancers.

Main Methods:

• Comprehensive literature review of studies involving sentinel lymph node biopsy for skin tumors.
• Analysis of existing data on the application and outcomes of SLNB in melanoma and nonmelanoma skin cancers.

Main Results:

• SLNB is well-established and prognostically significant in melanoma.
• Evidence supporting the routine use and prognostic value of SLNB in nonmelanoma skin cancers is currently limited.
• Further research is needed to establish the role of SLNB in nonmelanoma skin cancers.

Conclusions:

• Sentinel lymph node biopsy is a vital prognostic tool in melanoma management.
• The prognostic utility of sentinel lymph node biopsy in nonmelanoma skin cancers remains largely unproven and requires additional research.